Analyzing Diabetes Drugs Market in Germany: Opportunities and Growth Patterns 2026-2034

Diabetes Drugs Market in Germany by Insulins (Basal or Long Acting Insulins, Bolus or Fast Acting Insulins, Traditional Human Insulins, Biosimilar Insulins), by Oral Anti-diabetic drugs (Biguanides, Alpha-Glucosidase Inhibitors, Dopamine D2 receptor agonist, SGLT-2 inhibitors, DPP-4 inhibitors, Sulfonylureas, Meglitinides), by Non-Insulin Injectable drugs (GLP-1 receptor agonists, Amylin Analogue), by Germany Forecast 2026-2034

Aug 24 2025

Base Year: 2025

197 Pages

Key Insights

The German diabetes drugs market, valued at €4.06 billion in 2025, is projected to experience steady growth, driven by a rising prevalence of diabetes, an aging population, and increasing healthcare expenditure. The market's Compound Annual Growth Rate (CAGR) of 3.47% from 2025 to 2033 indicates a consistent expansion, although this rate may be influenced by factors such as pricing pressures, generic competition, and the introduction of innovative therapies. Key segments driving growth include GLP-1 receptor agonists, SGLT-2 inhibitors, and insulin analogs, reflecting a shift towards newer, more effective treatments with improved patient outcomes. The increasing adoption of combination therapies, aimed at optimizing glycemic control, is further boosting market expansion. Competition amongst major pharmaceutical players like Sanofi Aventis, Novo Nordisk A/S, Boehringer Ingelheim, and Eli Lilly fuels innovation and ensures a diverse range of treatment options. However, factors such as stringent regulatory approvals, high drug costs, and the potential for adverse effects can act as market restraints. Further analysis of regional variations within Germany, focusing on states like North Rhine-Westphalia, Bavaria, and Baden-Württemberg, which likely exhibit higher diabetes prevalence due to population density and demographics, will provide a more granular understanding of market dynamics.

The projected growth of the German diabetes drugs market hinges on several key factors. Continued research and development efforts leading to the introduction of novel therapies with enhanced efficacy and safety profiles will significantly impact the market landscape. Government initiatives focused on diabetes prevention and management, coupled with improved patient education and awareness campaigns, will play a vital role in shaping market demand. Furthermore, the market will be influenced by the evolving reimbursement policies and healthcare access patterns in Germany. A comprehensive understanding of these interwoven factors is essential for stakeholders to navigate the complexities of this dynamic market and make informed strategic decisions.

Diabetes Drugs Market in Germany Market Size and Forecast (2024-2030) — Diabetes Drugs Market in Germany Company Market Share

Diabetes Drugs Market in Germany: A Comprehensive Report (2019-2033)

This in-depth report provides a comprehensive analysis of the Diabetes Drugs market in Germany, covering market dynamics, growth trends, dominant segments, competitive landscape, and future outlook. The study period spans from 2019 to 2033, with 2025 serving as both the base and estimated year. This report is invaluable for pharmaceutical companies, investors, and healthcare professionals seeking to understand and capitalize on opportunities within this vital market. The report analyzes the parent market of pharmaceutical drugs in Germany and the child market of diabetes drugs, offering a granular view of market segmentation and competitive dynamics. Market values are presented in million units.

Diabetes Drugs Market in Germany Market Dynamics & Structure

The German diabetes drugs market is characterized by a moderately concentrated landscape, with key players such as Pfizer, Takeda, Janssen Pharmaceuticals, Eli Lilly, Novartis, Merck & Co, AstraZeneca, Sanofi Aventis, Bristol Myers Squibb, Novo Nordisk A/S, Boehringer Ingelheim, and Astellas holding significant market share. The market is driven by technological advancements in drug development, including novel therapies like GLP-1 receptor agonists and SGLT-2 inhibitors. Stringent regulatory frameworks imposed by the German health authorities (e.g., BfArM) influence market access and pricing. Competitive pressures arise from the availability of biosimilar insulins and the emergence of generic medications. The aging population and rising prevalence of diabetes are key demographic factors influencing market growth. M&A activity within the sector has been moderate in recent years, with approximately xx deals valued at xx million units completed between 2019 and 2024.

Market Concentration: Moderately concentrated, with top 10 players holding approximately 75% market share (estimated).
Technological Innovation: Significant advancements in GLP-1 receptor agonists, SGLT-2 inhibitors, and biosimilar insulins are driving growth.
Regulatory Framework: Stringent regulations impact pricing and market access.
Competitive Substitutes: Biosimilars and generic medications exert competitive pressure.
End-User Demographics: Aging population and rising prevalence of diabetes fuel market expansion.
M&A Trends: Moderate M&A activity, with xx deals completed between 2019 and 2024. Innovation barriers include high R&D costs and lengthy regulatory approval processes.

Diabetes Drugs Market in Germany Growth Trends & Insights

The German diabetes drugs market exhibited robust growth, achieving a Compound Annual Growth Rate (CAGR) of [Insert Precise CAGR for 2019-2024]% during the historical period (2019-2024), culminating in a market valuation of [Insert Precise Market Size in Euros/Units for 2024] in 2024. This expansion is primarily attributed to the escalating prevalence of diabetes within the German population, advancements in healthcare infrastructure, and the introduction of innovative therapies featuring superior efficacy and safety profiles. The market penetration of newer drug classes, such as GLP-1 receptor agonists and SGLT-2 inhibitors, has been particularly noteworthy, driven by their demonstrated cardiovascular benefits and improved glycemic control. Patient preference is increasingly shifting towards convenient treatment options, such as once-weekly injections, contributing to market dynamism. Furthermore, technological advancements, including the development of connected insulin delivery systems and continuous glucose monitoring (CGM) devices, are anticipated to further accelerate market growth. Looking ahead to the forecast period (2025-2033), a CAGR of [Insert Precise CAGR for 2025-2033]% is projected, with the market size expected to reach [Insert Precise Market Size in Euros/Units for 2033] by 2033. This projection incorporates factors such as increased healthcare expenditure, proactive government initiatives aimed at enhancing diabetes management, and the expanding adoption of digital health solutions in diabetes care.

Dominant Regions, Countries, or Segments in Diabetes Drugs Market in Germany

The German diabetes drugs market shows robust growth across various segments. However, the Non-Insulin Injectable drugs segment, particularly GLP-1 receptor agonists, demonstrates exceptional growth potential due to their effectiveness in managing both blood glucose levels and cardiovascular risk. Within the Oral Anti-diabetic drugs segment, SGLT-2 inhibitors like Suglat (Ipragliflozin) show considerable promise because of its efficacy and patient preference. The strong growth of these segments is underpinned by several factors: increased awareness of the benefits of these therapies among healthcare professionals and patients, favourable reimbursement policies, and a large patient population with type 2 diabetes.

Key Growth Drivers:
- High prevalence of type 2 diabetes in Germany.
- Increasing awareness among both patients and healthcare professionals about the benefits of newer therapies.
- Favorable reimbursement policies and improved access to medicines.
- Growing focus on the prevention of cardiovascular complications associated with diabetes.
Dominant Segments:
- Non-Insulin Injectable drugs (GLP-1 receptor agonists): This segment dominates due to superior efficacy and patient adherence. Market share is projected to be xx% by 2033.
- SGLT-2 inhibitors: Rapid growth due to efficacy in cardiovascular risk reduction, with projected market share of xx% by 2033.
- Oral Anti-diabetic Drugs: Continues to hold a significant share, driven by cost-effectiveness of some treatments; however, this segment's growth is expected to be slower than the injectable segments.

Diabetes Drugs Market in Germany Product Landscape

The German diabetes drugs market presents a diverse product portfolio, encompassing a wide range of insulin types (basal, bolus, and increasingly prevalent biosimilars), oral anti-diabetic drugs (including biguanides, sulfonylureas, meglitinides, DPP-4 inhibitors, and SGLT-2 inhibitors), and non-insulin injectables (GLP-1 receptor agonists and amylin analogues). Ongoing innovation is focused on enhancing efficacy, safety, and convenience (e.g., extended-release formulations and once-weekly injections), while simultaneously minimizing adverse effects. The introduction of combination therapies, such as Xultophy, and the expanding availability of biosimilar insulins have significantly impacted the market dynamics, offering cost-effective alternatives without compromising therapeutic efficacy. Moreover, the integration of advanced technologies such as smart insulin pens and continuous glucose monitors (CGMs) is revolutionizing patient management, improving treatment adherence, and fostering further market expansion.

Key Drivers, Barriers & Challenges in Diabetes Drugs Market in Germany

Key Drivers: The escalating prevalence of diabetes in Germany, coupled with significant advancements in drug development, particularly GLP-1 receptor agonists and SGLT-2 inhibitors with proven cardiovascular benefits, are major growth catalysts. Supportive reimbursement policies and the rising awareness among healthcare professionals and patients regarding the advantages of newer treatment options contribute substantially to market expansion. The increasing focus on preventative care and early intervention strategies also fuels demand.

Challenges: High drug prices, especially for innovative therapies, pose a significant barrier. The growing presence of biosimilars intensifies competition and puts downward pressure on prices. Stringent regulatory processes and lengthy approval timelines for new drugs create hurdles for market entry. Furthermore, potential supply chain disruptions can affect medication availability, potentially impacting patient care and treatment continuity.

Emerging Opportunities in Diabetes Drugs Market in Germany

The market presents opportunities in personalized medicine approaches to diabetes management. The increasing adoption of digital health technologies, including remote patient monitoring and telemedicine, creates new avenues for improved patient care and market expansion. Underexplored patient segments, such as those with specific comorbidities or ethnic backgrounds, represent potential untapped markets. Focus on patient education and improved adherence to treatment regimens is crucial for maximizing the benefits of available therapies.

Growth Accelerators in the Diabetes Drugs Market in Germany Industry

Technological breakthroughs, particularly in personalized medicine and connected devices, are pivotal growth accelerators. Strategic alliances between pharmaceutical companies and technology providers offer opportunities to enhance treatment efficacy and accessibility. Expanding market access through collaborations with healthcare providers and government agencies is also a key strategic imperative. The continuing focus on developing drugs with demonstrated cardiovascular benefits is projected to further drive segment growth. The integration of digital health solutions for remote patient monitoring and data-driven insights will also contribute to accelerating market expansion.

Key Players Shaping the Diabetes Drugs Market in Germany Market

Notable Milestones in Diabetes Drugs Market in Germany Sector

March 2022: Eli Lilly and Boehringer Ingelheim gained EU approval for heart failure treatment for Jardiance (empagliflozin), a sodium-glucose co-transporter-2-inhibitor. This significantly expanded the market for this drug.
February 2023: AstraZeneca's Forxiga (dapagliflozin) received expanded EU approval for heart failure treatment across the full spectrum of left ventricular ejection fraction, boosting its market potential.

In-Depth Diabetes Drugs Market in Germany Market Outlook

The German diabetes drugs market is poised for sustained growth, propelled by continuous innovation in drug development, an expanding patient population, and increasing healthcare expenditure. Promising opportunities lie in personalized medicine, the seamless integration of digital health technologies, and targeting underserved patient segments. Strategic partnerships and initiatives aimed at broadening market access will be instrumental in shaping the future trajectory of this dynamic market. The growing emphasis on the cardiovascular benefits associated with specific diabetes medications is expected to further fuel market growth in the coming years. Furthermore, the increasing focus on preventative care and improved patient education initiatives will contribute to shaping the market’s future landscape.

Diabetes Drugs Market in Germany Segmentation

1. Insulins
- 1.1. Basal or Long Acting Insulins
- 1.2. Bolus or Fast Acting Insulins
- 1.3. Traditional Human Insulins
- 1.4. Biosimilar Insulins
2. Oral Anti-diabetic drugs
- 2.1. Biguanides
- 2.2. Alpha-Glucosidase Inhibitors
- 2.3. Dopamine D2 receptor agonist
- 2.4. SGLT-2 inhibitors
- 2.5. DPP-4 inhibitors
- 2.6. Sulfonylureas
- 2.7. Meglitinides
3. Non-Insulin Injectable drugs
- 3.1. GLP-1 receptor agonists
- 3.2. Amylin Analogue

Diabetes Drugs Market in Germany Segmentation By Geography

1. Germany

Diabetes Drugs Market in Germany Market Share by Region - Global Geographic Distribution — Diabetes Drugs Market in Germany Regional Market Share

Geographic Coverage of Diabetes Drugs Market in Germany

Higher Coverage

Lower Coverage

No Coverage

Diabetes Drugs Market in Germany REPORT HIGHLIGHTS

Aspects	Details
Study Period	2020-2034
Base Year	2025
Estimated Year	2026
Forecast Period	2026-2034
Historical Period	2020-2025
Growth Rate	CAGR of 3.47% from 2020-2034
Segmentation	By Insulins Basal or Long Acting Insulins Bolus or Fast Acting Insulins Traditional Human Insulins Biosimilar Insulins By Oral Anti-diabetic drugs Biguanides Alpha-Glucosidase Inhibitors Dopamine D2 receptor agonist SGLT-2 inhibitors DPP-4 inhibitors Sulfonylureas Meglitinides By Non-Insulin Injectable drugs GLP-1 receptor agonists Amylin Analogue By Geography Germany

1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
- 2.1. Introduction
3. Market Dynamics
- 3.1. Introduction
- - 3.2. Market Drivers
  - - 3.2.1. ; The Rise in Global Prevalence of Cases of Obesity due to Modern Sedentary Lifestyles; Rise in Awareness and Disposable Income in Developed Economies
- - 3.3. Market Restrains
  - - 3.3.1 ; Highly Cost of Branded Products in Emerging Countries; Severe Adverse Associated with Medication Including Seizures
    - 3.3.2 Suicidal Attempts and Even Death; Adoption of Traditional Yoga and Herbal Products
- - 3.4. Market Trends
  - - 3.4.1. The oral anti-diabetic drugs segment holds the highest market share in the Germany Diabetes Drugs Market in the current year
4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
5. Diabetes Drugs Market in Germany Analysis, Insights and Forecast, 2020-2032
- 5.1. Market Analysis, Insights and Forecast - by Insulins
  - 5.1.1. Basal or Long Acting Insulins
  - 5.1.2. Bolus or Fast Acting Insulins
  - 5.1.3. Traditional Human Insulins
  - 5.1.4. Biosimilar Insulins
- 5.2. Market Analysis, Insights and Forecast - by Oral Anti-diabetic drugs
  - 5.2.1. Biguanides
  - 5.2.2. Alpha-Glucosidase Inhibitors
  - 5.2.3. Dopamine D2 receptor agonist
  - 5.2.4. SGLT-2 inhibitors
  - 5.2.5. DPP-4 inhibitors
  - 5.2.6. Sulfonylureas
  - 5.2.7. Meglitinides
- 5.3. Market Analysis, Insights and Forecast - by Non-Insulin Injectable drugs
  - 5.3.1. GLP-1 receptor agonists
  - 5.3.2. Amylin Analogue
- 5.4. Market Analysis, Insights and Forecast - by Region
  - 5.4.1. Germany
6. Competitive Analysis
- 6.1. Market Share Analysis 2025
- - 6.2. Company Profiles
  - - 6.2.1 Pfizer
      6.2.1.1. Overview
      6.2.1.2. Products
      6.2.1.3. SWOT Analysis
      6.2.1.4. Recent Developments
      6.2.1.5. Financials (Based on Availability)
    - 6.2.2 Takeda
      6.2.2.1. Overview
      6.2.2.2. Products
      6.2.2.3. SWOT Analysis
      6.2.2.4. Recent Developments
      6.2.2.5. Financials (Based on Availability)
    - 6.2.3 Other
      6.2.3.1. Overview
      6.2.3.2. Products
      6.2.3.3. SWOT Analysis
      6.2.3.4. Recent Developments
      6.2.3.5. Financials (Based on Availability)
    - 6.2.4 Janssen Pharmaceuticals
      6.2.4.1. Overview
      6.2.4.2. Products
      6.2.4.3. SWOT Analysis
      6.2.4.4. Recent Developments
      6.2.4.5. Financials (Based on Availability)
    - 6.2.5 Eli Lilly
      6.2.5.1. Overview
      6.2.5.2. Products
      6.2.5.3. SWOT Analysis
      6.2.5.4. Recent Developments
      6.2.5.5. Financials (Based on Availability)
    - 6.2.6 Novartis
      6.2.6.1. Overview
      6.2.6.2. Products
      6.2.6.3. SWOT Analysis
      6.2.6.4. Recent Developments
      6.2.6.5. Financials (Based on Availability)
    - 6.2.7 Merck and Co
      6.2.7.1. Overview
      6.2.7.2. Products
      6.2.7.3. SWOT Analysis
      6.2.7.4. Recent Developments
      6.2.7.5. Financials (Based on Availability)
    - 6.2.8 AstraZeneca
      6.2.8.1. Overview
      6.2.8.2. Products
      6.2.8.3. SWOT Analysis
      6.2.8.4. Recent Developments
      6.2.8.5. Financials (Based on Availability)
    - 6.2.9 Sanofi Aventis
      6.2.9.1. Overview
      6.2.9.2. Products
      6.2.9.3. SWOT Analysis
      6.2.9.4. Recent Developments
      6.2.9.5. Financials (Based on Availability)
    - 6.2.10 Bristol Myers Squibb
      6.2.10.1. Overview
      6.2.10.2. Products
      6.2.10.3. SWOT Analysis
      6.2.10.4. Recent Developments
      6.2.10.5. Financials (Based on Availability)
    - 6.2.11 Novo Nordisk A/S
      6.2.11.1. Overview
      6.2.11.2. Products
      6.2.11.3. SWOT Analysis
      6.2.11.4. Recent Developments
      6.2.11.5. Financials (Based on Availability)
    - 6.2.12 Boehringer Ingelheim
      6.2.12.1. Overview
      6.2.12.2. Products
      6.2.12.3. SWOT Analysis
      6.2.12.4. Recent Developments
      6.2.12.5. Financials (Based on Availability)
    - 6.2.13 Sanofi Aventis
      6.2.13.1. Overview
      6.2.13.2. Products
      6.2.13.3. SWOT Analysis
      6.2.13.4. Recent Developments
      6.2.13.5. Financials (Based on Availability)
    - 6.2.14 Astellas
      6.2.14.1. Overview
      6.2.14.2. Products
      6.2.14.3. SWOT Analysis
      6.2.14.4. Recent Developments
      6.2.14.5. Financials (Based on Availability)

List of Figures

Figure 1: Diabetes Drugs Market in Germany Revenue Breakdown (Million, %) by Product 2025 & 2033
Figure 2: Diabetes Drugs Market in Germany Share (%) by Company 2025

List of Tables

Table 1: Diabetes Drugs Market in Germany Revenue Million Forecast, by Insulins 2020 & 2033
Table 2: Diabetes Drugs Market in Germany Revenue Million Forecast, by Oral Anti-diabetic drugs 2020 & 2033
Table 3: Diabetes Drugs Market in Germany Revenue Million Forecast, by Non-Insulin Injectable drugs 2020 & 2033
Table 4: Diabetes Drugs Market in Germany Revenue Million Forecast, by Region 2020 & 2033
Table 5: Diabetes Drugs Market in Germany Revenue Million Forecast, by Insulins 2020 & 2033
Table 6: Diabetes Drugs Market in Germany Revenue Million Forecast, by Oral Anti-diabetic drugs 2020 & 2033
Table 7: Diabetes Drugs Market in Germany Revenue Million Forecast, by Non-Insulin Injectable drugs 2020 & 2033
Table 8: Diabetes Drugs Market in Germany Revenue Million Forecast, by Country 2020 & 2033

Frequently Asked Questions

1. What is the projected Compound Annual Growth Rate (CAGR) of the Diabetes Drugs Market in Germany?

The projected CAGR is approximately 3.47%.

2. Which companies are prominent players in the Diabetes Drugs Market in Germany?

Key companies in the market include Pfizer, Takeda, Other, Janssen Pharmaceuticals, Eli Lilly, Novartis, Merck and Co, AstraZeneca, Sanofi Aventis, Bristol Myers Squibb, Novo Nordisk A/S, Boehringer Ingelheim, Sanofi Aventis, Astellas.

3. What are the main segments of the Diabetes Drugs Market in Germany?

The market segments include Insulins, Oral Anti-diabetic drugs, Non-Insulin Injectable drugs.

4. Can you provide details about the market size?

The market size is estimated to be USD 4.06 Million as of 2022.

5. What are some drivers contributing to market growth?

; The Rise in Global Prevalence of Cases of Obesity due to Modern Sedentary Lifestyles; Rise in Awareness and Disposable Income in Developed Economies.

6. What are the notable trends driving market growth?

The oral anti-diabetic drugs segment holds the highest market share in the Germany Diabetes Drugs Market in the current year.

7. Are there any restraints impacting market growth?

; Highly Cost of Branded Products in Emerging Countries; Severe Adverse Associated with Medication Including Seizures. Suicidal Attempts and Even Death; Adoption of Traditional Yoga and Herbal Products.

8. Can you provide examples of recent developments in the market?

February 2023: AstraZeneca's Forxiga (dapagliflozin) was approved in the European Union to extend the indication for heart failure with reduced ejection fraction to cover patients across the full spectrum of left ventricular ejection fraction. It includes HF with mildly reduced and preserved ejection fraction.

9. What pricing options are available for accessing the report?

Pricing options include single-user, multi-user, and enterprise licenses priced at USD 3800, USD 4500, and USD 5800 respectively.

10. Is the market size provided in terms of value or volume?

The market size is provided in terms of value, measured in Million.

11. Are there any specific market keywords associated with the report?

Yes, the market keyword associated with the report is "Diabetes Drugs Market in Germany," which aids in identifying and referencing the specific market segment covered.

12. How do I determine which pricing option suits my needs best?

The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.

13. Are there any additional resources or data provided in the Diabetes Drugs Market in Germany report?

While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.

14. How can I stay updated on further developments or reports in the Diabetes Drugs Market in Germany?

To stay informed about further developments, trends, and reports in the Diabetes Drugs Market in Germany, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.

Methodology

Step 1 - Identification of Relevant Samples Size from Population Database

Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)

Top-down and bottom-up approaches are used to validate the global market size and estimate the market size for manufactures, regional segments, product, and application.

Note*: In applicable scenarios

Step 3 - Data Sources

Primary Research

Web Analytics
Survey Reports
Research Institute
Latest Research Reports
Opinion Leaders

Secondary Research

Annual Reports
White Paper
Latest Press Release
Industry Association
Paid Database
Investor Presentations

Step 4 - Data Triangulation

Involves using different sources of information in order to increase the validity of a study

These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.

Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.

During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence

Additionally, after gathering mixed and scattered data from a wide range of sources, data is triangulated and correlated to come up with estimated figures which are further validated through primary mediums or industry experts, opinion leaders.

About Insight Market Reports

Insight Market Reports is your gateway to reliable market intelligence and strategic business insights. Our platform is dedicated to providing businesses, investors, and professionals with timely, accurate, and actionable market research that drives success. We pride ourselves on our comprehensive industry coverage, spanning technology, healthcare, energy, finance, consumer goods, automotive, and manufacturing.

Our reports are crafted by seasoned analysts who blend primary research, expert interviews, and data analytics to deliver the clarity and foresight you need. Whether you’re seeking syndicated market reports, custom research, or consulting services, Insight Market Reports offers solutions tailored to your unique business needs.

We are committed to quality, integrity, and client satisfaction. Every report undergoes stringent validation and peer review, ensuring you receive only the most relevant and trustworthy insights. Our global perspective and local expertise help you understand both macro trends and micro market dynamics.

Stay ahead of the competition with Insight Market Reports. Subscribe to our newsletter for the latest industry updates, expert commentary, and exclusive research highlights. Follow us on social media to join a community of forward-thinking professionals and stay informed about the trends shaping your industry.

Insight Market Reports – Empowering Your Business with Intelligence That Drives Results.